The Clinical Effect of Bosingunyang-tang on Chronic Non-bacterial Prostatitis/Chronic Pelvic Pain Syndrome : Randomized Double-blind, Placebo-controlled Clinical Trial
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective : Although chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS) is a common disease, there is no consensus on the etiology or pathology and treatment. This was a double-blinded, placebo-controlled, randomized clinical trial, investigating the therapeutic effects of the traditional Korean medicine, Bosingunyang-tang(BSGYT). Method : Participants who met US National Institutes of Health (NIH) consensus criteria for CP/CPPS were entered after applying inclusion/exclusion criteria. They were randomized to the BSGYT or placebo group, and treated three times a day for 6 weeks. NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) was used to estimate the clinical symptoms of CP/CPPS. Prostaglandin E2 and β-endorphin in prostatic fluid, collected by 2-glass pre-massage and post-massage test, were analyzed as factors associated with pain and inflammation. Result : The mean decrease in NIH-CPSI total score of the BSGYT group was 11.0 points, which is 5.7 points more than the placebo group. (Mann Whitney test P=0.038) Also the BSGYT group showed three times higher response rate than the placebo group in NIH-CPSI pain subscale score. (Fisher's exact test P=0.027) In those responders, prostaglandin E2 decreased significantly. (Wilcoxon's signed-ranks test P=0.037). No specific side effects were observed. Conclusion : After a 6-week treatment period, BSGYT improved clinical symptoms of CP/CPPS patients by decreasing PGE2 level in prostatic fluid.
Abstract
Objective : Although chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS) is a common disease, there is no consensus on the etiology or pathology and treatment. This was a double-blinded, placebo-controlled, randomized clinical trial, investigating the therapeutic effects of the traditional Korean medicine, Bosingunyang-tang(BSGYT). Method : Participants who met US National Institutes of Health (NIH) consensus criteria for CP/CPPS were entered after applying inclusion/exclusion criteria. They were randomized to the BSGYT or placebo group, and treated three times a day for 6 weeks. NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) was used to estimate the clinical symptoms of CP/CPPS. Prostaglandin E2 and β-endorphin in prostatic fluid, collected by 2-glass pre-massage and post-massage test, were analyzed as factors associated with pain and inflammation. Result : The mean decrease in NIH-CPSI total score of the BSGYT group was 11.0 points, which is 5.7 points more than the placebo group. (Mann Whitney test P=0.038) Also the BSGYT group showed three times higher response rate than the placebo group in NIH-CPSI pain subscale score. (Fisher's exact test P=0.027) In those responders, prostaglandin E2 decreased significantly. (Wilcoxon's signed-ranks test P=0.037). No specific side effects were observed. Conclusion : After a 6-week treatment period, BSGYT improved clinical symptoms of CP/CPPS patients by decreasing PGE2 level in prostatic fluid.
참고문헌 (29)
- Roberts RO, "A review of clinical and pathological prostatitis syndromes", Urology, 49(6), pp.809~821 (1997)
- Schaeffer AJ, "Etiology and management of chronic pelvic pain syndrome in men", Urology, 63, pp.75~84 (2004)
- Alexander RB, "Ciprofloxacin or tamsulosin in men with chronic prostatitis", chronic pelvic pain syndrome: a randomized, double-blind trial, 2004, pp.141(8), 581~589
- Krieger JN, "NIH consensus definition and classification of prostatitis", JAMA, 282(3), pp.236~237 (1999)
- Collins MM, "Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: results of a national survey of physician visits", Urology, 53(5), pp.921~925 (1999)
- Krieger JN, "Chronic pelvic pains represent the most prominent urogenital symptoms of "chronic prostatitis", Urology, 48(5), pp.715~721 (1996)
- Wenninger K, "Sickness impact of chronic nonbacterial prostatitis and its correlates", J Urol, 155(3), pp.965~968 (1996)
- Schaeffer AJ, "Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome", N Engl J Med, 355(16), pp.1690~1698 (2006)
- Ku JH, "Chronic prostatitis in Korea: a nationwide postal survey of practicing urologists in 2004", Asian J Androl, 7(4), pp.427~432 (2004)
- Mehik A, "Alfuzosin treatment for chronic prostatitis", chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study, 2003, pp.62(3), 425~429
- Pontari MA, "Mechanisms in prostatitis", chronic pelvic pain syndrome, 2008, pp.179(5), S61~S671
- Capodice JL, "Complementary and alternative medicine for chronic prostatitis", chronic pelvic pain syndrome, 2005, pp.2(4), 495~501
- Propert KJ, "Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI)", Qual Life Res, 15(2), pp.299~305 (2006)
- Nickel JC, "Psychosocial variables affect the quality of life of men diagnosed with chronic prostatitis", chronic pelvic pain syndrome, 2008, pp.101(1), 59~64
- Berger RE, "Pelvic tenderness is not limited to the prostate in chronic prostatitis", chronic pelvic pain syndrome (CPPS) type IIIA and IIIB: comparison of men with and without CP, BMC Urol, pp.2007, 7[DOI]
- Capodice JL, "Stone BA, Kapan S, et al. A pilot study on acupuncture for lower urinary tract symptoms related to chronic prostatitis", chronic pelvic pain, 2007, pp.2, 1~
- Jin UH, "Herbal formulation, Yukmi-jihang-tang-Jahage, regulates bone resorption by inhibition of phosphorylation mediated by tyrosine kinase Src and cyclooxygenase expression", J Ethnopharmacol, 106(3), pp.333~343 (2006)
- Kim JH, "Decursin inhibits induction of inflammatory mediators by blocking nuclear factor-kappaB activation in macrophages", Mol Pharmacol, 69(9), pp.1783~1790 (2006)
- Lin RD, "Inhibition of monoamine oxidase B (MAO-B) by Chinese herbal medicines", Phytomedicine, 10(8), pp.650~656 (2003)
- Lee SWH, "Acupuncture versus sham acupuncture for chronic prostatitis", chronic pelvic pain, 2008, pp.121(1), e1~e7
- Shoskes DA, "Quercetin in men with category III chronic prostatitis: a preliminary prospective, double- blind, placebo-controlled trial", Urology, 54(6), pp.960~963 (1999)
- Jang TL, "The role of cytokines in prostatitis", World J Urol, 21(2), pp.95~99 (2003)
- Vlaskovska M, "Adrenocorticotropin and beta-endorphin release from rat adenohypophysis in vitro: inhibition by prostaglandin E2 formed locally in response to vasopressin and corticotropin-releasing factor", Endocrinology, 115(3), pp.895~903 (1984)
- Nickel JC, "How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis", chronic pelvic pain syndrome?, 2006, pp.176(1), 119~124
- Chen JX, "Traditional chinese medicine for the treatment of chronic prostatitis in China: a systematic review and meta-analysis", Journal of Alternative and Complementary Medicine, 12(8), pp.763~769 (2006)
- Nickel JC, "Inflammation and benign prostatic hyperplasia", Urol. Clin. North Am, 35(1), pp.109~115 (2008)
- Chong CH, "The Korean version of NIH-Chronic Prostatitis Symptom Index (NIH-CPSI): validation study and characteristics on chronic prostatitis", Korean J Urol, 42, pp.511~520 (2001)
- Nickel JC, "A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis)", BJU Int, 93(7), pp.991~995 (2004)
- Schaeffer AJ, "NIDDK-sponsored chronic prostatitis collaborative research network (CPCRN) 5-year data and treatment guidelines for bacterial prostatitis", Int J Antimicrob Agents, 24(1), pp.S49~S52 (2004)